Literature DB >> 23647081

Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.

Holly Geyer1, Keith Cannon, Emily Knight, Veena Fauble, John Camoriano, Robyn Emanuel, Raoul Tibes, Ruben Mesa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23647081     DOI： 10.3109/10428194.2013.789507

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Authors:  Kiran Naqvi; Naval Daver; Naveen Pemmaraju; Prithviraj Bose; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2016-08-05

2.  Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.

Authors:  Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-08-05

3.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Authors:  Allison H Scotch; Heidi Kosiorek; Robyn Scherber; Amylou C Dueck; Stefanie Slot; Sonja Zweegman; Peter A W Te Boekhorst; Suzan Commandeur; Harry Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa; Holly L Geyer
Journal:  Leuk Res       Date:  2017-10-14       Impact factor: 3.156

Review 4.  Ruxolitinib dose management as a key to long-term treatment success.

Authors:  Ruben A Mesa; Rami S Komrokji; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-08-27       Impact factor: 2.490

Review 5.  Ruxolitinib for myelofibrosis--an update of its clinical effects.

Authors:  Hagop M Kantarjian; Richard T Silver; Rami S Komrokji; Ruben A Mesa; Roland Tacke; Claire N Harrison
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-02

Review 6.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

7.  Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.

Authors:  Srdan Verstovsek
Journal:  Oncology (Williston Park)       Date:  2013-07       Impact factor: 2.990

8.  Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Authors:  Keith L Davis; Isabelle Côté; James A Kaye; Estella Mendelson; Haitao Gao; Julian Perez Ronco
Journal:  Adv Hematol       Date:  2015-11-09

Review 9.  Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.

Authors:  Ryan Eckert; Jennifer Huberty; Krisstina Gowin; Ruben Mesa; Lisa Marks
Journal:  Integr Cancer Ther       Date:  2016-07-24       Impact factor: 3.279

10.  Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

Authors:  Nur Soyer; Rıdvan Ali; Mehmet Turgut; İbrahim Celalettin Haznedaroğlu; Fergün Yılmaz; İsmet Aydoğdu; Ali Pir; Volkan Karakuş; Gökhan Özgür; Cem Kiş; Funda Ceran; Gül İlhan; Melda Özkan; Müzeyyen Aslaner; İdris İnce; İrfan Yavaşoğlu; Füsun Gediz; Mehmet Sönmez; Birol Güvenç; Gülsüm Özet; Emin Kaya; Filiz Vural; Fahri Şahin; Mahmut Töbü; Raika Durusoy; Güray Saydam
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.